Meta-analysis of randomized clinical trials comparing robotic versus laparoscopic surgery for mid-low rectal cancers

Abstract

Introduction

Robotic surgery (RS) is experiencing major development, particularly in the context of rectal cancer. The aim of this meta-analysis was to summarize data from the literature, focusing specifically on the safety and effectiveness of robotic surgery in mid-low rectal cancers, based on the hypothesis that that robotic surgery can find its most rational indication in this anatomical location.

Method

The meta-analysis was conducted according to the PRISMA 2000 recommendations, including all randomized trials that compared robotic surgery versus laparoscopic surgery (LS) that were found in the Medline-PICO, Cochrane Database, Scopus and Google databases. Data were extracted independently by two reviewers. The risk of bias was analyzed according to the Cochrane Handbook method and the certainty of the evidence according to the GRADE method. The analysis was carried out with R software Version 4.2-3 using the Package for Meta-Analysis “meta” version 6.5-0.

Results

Eight randomized trials were included (with a total of 2342 patients), including four that focused specifically on mid-low rectal cancer (n = 1,734 patients). No statistically significant difference was found for overall morbidity, intra-operative morbidity, anastomotic leakage, post-operative mortality, quality of mesorectal specimen, and resection margins. The main differences identified were a lower conversion rate for RS (RR = 0.48 [0.24–0.95], p = 0.04, I² = 0%), and a longer operative time for RS (mean difference = 39.11 min [9.39–68.83], p < 0.01, I² = 96%). The other differences had no real clinical relevance, i.e., resumption of flatus passage (5 hours earlier after RS), and lymph node dissection (one more lymph node for LS).

Conclusion

This meta-analysis does not confirm the initial hypothesis and does not show a statistically significant or clinically relevant benefit of RS compared to LS for mid-low rectal cancer.